Napo Therapeutics, S.p.a.

This phase 2 trial tests crofelemer, a plant-based oral powder, in 18 adults with short bowel syndrome and intestinal failure who rely on IV nutrition. Participants receive either a low dose, a higher dose, or a placebo for 24 weeks. The goal is to see if crofelemer safely reduce…